Ocular Therapeutix, Inc. (OCUL) Cash Flow Statement
Ocular Therapeutix, Inc. (OCUL) generated -$238.2M of operating cash flow over the twelve months to 2026-06-30, spent $16.9M on capital expenditure and had free cash flow of -$255.1M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
OCULOcular Therapeutix, Inc.Follow OCUL — free
—
Price chart with a free account
- Market cap
- 1.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -20.5 | -33.7 | -34.0 | -50.5 | -49.2 | -77.6 | -53.6 | -65.6 | -59.6 | -70.2 | -134.7 | -204.9 | -238.2 | |
| Capital expenditure | 1.3 | 1.8 | 1.9 | 8.3 | 1.9 | 2.2 | 0.8 | 1.2 | 3.7 | 6.1 | 1.3 | 12.0 | -16.9 | |
| Free cash flow | -21.8 | -35.5 | -35.9 | -58.7 | -51.1 | -79.8 | -54.4 | -66.7 | -63.3 | -76.3 | -136.0 | -216.9 | -255.1 | |
| Stock-based compensation | 2.6 | 4.6 | 6.0 | 7.3 | 7.5 | 8.8 | 7.5 | 15.0 | 17.0 | 17.8 | 33.1 | 43.2 | — |
USD millions · SEC XBRL
Ocular Therapeutix, Inc. — questions
- What is Ocular Therapeutix, Inc.'s operating cash flow?
- -$238.2M over the twelve months to 2026-06-30.
- How much does Ocular Therapeutix, Inc. spend on capital expenditure?
- $16.9M over the twelve months to 2026-06-30.
- What is Ocular Therapeutix, Inc.'s free cash flow?
- -$255.1M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Ocular Therapeutix, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.